

Serial No.: 09/807,657
Group Art Unit No.: 1648

40. (Amended) A process for the manufacture of a vaccine composition as claimed in claim 39, wherein the second antigen is adsorbed onto a second metallic salt particle wherein the metallic salt of each of the first metallic salt particle and the second metallic salt particle may be the same.

41. (Amended) A process as claimed in claims 39, wherein the second antigen is selected from the group comprising: antigens derived from Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex Virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, IgE peptides, Der p1, pollen related antigens; or Tumor associated antigens (TAA), MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRh (GnRH), CEA, PSA, KSA, or PRAME.

42. (Amended) A vaccine composition comprising an adjuvant composition according to any one of claims 32 to 37, additionally comprising a second antigen wherein the first antigen and the second antigen may be the same.

71. (Amended) A vaccine composition as claimed in claim 42, wherein the second antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

72. (Amended) A vaccine composition as claimed in claim 43, wherein the second antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella,

Serial No.: 09/807,657
Group Art Unit No.: 1648

Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

Sub. E 73. (Amended) A vaccine composition as claimed in claim 44, wherein the second antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

74. (Amended) A vaccine composition as claimed in claim 45, wherein the second antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

75. (Amended) A vaccine composition as claimed in claim 46, wherein the second antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

Serial No.: 09/807,657
Group Art Unit No.: 1648

76. (Amended) A vaccine composition as claimed in claim 47, wherein the second antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

Sub 42
77. (Amended) A vaccine composition as claimed in claim 48, wherein the second antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

Q4
78. (Amended) A vaccine composition as claimed in claim 49, wherein the second antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

79. (Amended) A vaccine composition as claimed in claim 50, wherein the second antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella,

Serial No.: 09/807,657
Group Art Unit No.: 1648

Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

Sub E2
80. (Amended) A vaccine composition as claimed in claim 51, wherein the second antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

204
81. (Amended) A vaccine composition as claimed in claim 52, wherein the second antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

82. (Amended) A vaccine composition as claimed in claim 71, wherein the second antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

83. (Amended) A vaccine composition as claimed in claim 72, wherein the second antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

84. (Amended) A vaccine composition as claimed in claim 73, wherein the second antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

Serial No.: 09/807,657
Group Art Unit No.: 1648

85. (Amended) A vaccine composition as claimed in claim 74, wherein the second antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

86. (Amended) A vaccine composition as claimed in claim 75, wherein the second antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

87. (Amended) A vaccine composition as claimed in claim 76, wherein the second antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

88. (Amended) A vaccine composition as claimed in claim 77, wherein the second antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

89. (Amended) A vaccine composition as claimed in claim 78, wherein the second antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

90. (Amended) A vaccine composition as claimed in claim 79, wherein the second antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

91. (Amended) A vaccine composition as claimed in claim 80, wherein the second antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

92. (Amended) A vaccine composition as claimed in claim 81, wherein the second antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

Please add new claims 116-119 as follows:

116. (Added) An adjuvant composition comprising: a) an immunostimulant adsorbed onto a metallic salt particle, wherein the immunostimulant may be a first antigen and is selected from the group consisting of bacterially derived compounds, monophosphoryl lipid A, immunostimulatory oligonucleotides, CpG, block copolymers, cholera toxin, immunostimulatory cytokines, GM-CSF, IL-1, polyriboA, polyriboU, and Muramyl tripeptide, and b) a second antigen, wherein the second antigen is not adsorbed onto the metallic salt particle.

Serial No.: 09/807,657
Group Art Unit No.: 1648

117. (Added) A process for the manufacture of a vaccine composition comprising the admixture of a) an adjuvant composition comprising an immunostimulant adsorbed onto a metallic salt particle, wherein the immunostimulant may be a first antigen and is selected from the group consisting of bacterially derived compounds, monophosphoryl lipid A, immunostimulatory oligonucleotides, CpG, block copolymers, cholera toxin, immunostimulatory cytokines, GM-CSF, IL-1, polyriboA, polyriboU, and Muramyl tripeptide, and b) a second antigen wherein the second antigen is not absorbed onto the metallic salt particle and the first antigen and the second antigen may be the same.

118. (Added) An adjuvant composition comprising an immunostimulant adsorbed onto a metallic salt particle, wherein the metallic salt particle is substantially free of antigen and in that the immunostimulant is not a saponin derived from the bark of Quillaja Saponaria Molina.

119. (Added) A process for the manufacture of a vaccine composition comprising the admixture of a) an adjuvant composition comprising an immunostimulant adsorbed onto a metallic salt particle, and b) an antigen.